课题基金 / 基金详情

THERAPY OF WILSONS DISEASE W/ TETRATHIOMOLYBDATE COMPARISON W/ TRIENTINE

THERAPY OF WILSONS DISEASE W/ TETRATHIOMOLYBDATE COMPARISON W/ TRIENTINE
四硫代钼酸盐治疗威尔逊病与曲恩汀的比较
批准号:
6303500
负责人:
GEORGE J BREWER
金额:
$0.02万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-12-01 至 2001-02-28

项目摘要

项目成果

GEORGE J BREWER的其他基金

相似基金

相关文献

中文摘要
翻译
最近FDA批准了醋酸锌,这很好地涵盖了威尔逊病的维持疗法。然而,对表现为神经系统疾病的患者的初始治疗是有问题的。锌的作用相当缓慢,急病患者的病情可能会在锌控制铜中毒之前进展。治疗威尔逊氏病使用时间最长的铜络合剂青霉胺对这些患者来说是极其危险的。铜络合剂曲恩汀的使用有限,但似乎比青霉胺的副作用更少。最初的恶化还没有报道,尽管理论上三丁胺有风险。我们已经推出了一种新的孤儿药物(四硫钼酸盐,或TM)用于这些患者的初步治疗。TM具有快速起效的理想特性,并且不会导致最初的恶化。在这里,我们提出了一项为期3年的、III期双盲、两个部位的研究,比较TM和曲宁汀对神经科表现的患者的初始治疗。我们计划了一项有90名患者参加的试验,每只手臂45名。需要回答的主要问题是:最初的神经恶化速度是否存在差异?第一年和第二年的神经恢复程度有差异吗?严重副作用的发生率是否存在差异?在研究完成时,我们不仅将回答与TM和Trientine有关的问题,而且我们将确定已上市的药物Trientine在最初治疗环境中的疗效和毒性。
英文摘要
The maintenance therapy of Wilson's disease is now well covered with the recent FDA approval of zinc acetate. However, the initial therapy of patients presenting with neurologic disease is problematic. Zinc is rather slow-acting and the disease of the acutely ill patient may progress prior to zinc controlling copper toxicity. The copper chelator that has been used the longest for Wilson's disease, penicillamine, is extremely dangerous for these patients. The copper chelator, trientine, has seen limited use, but seems to have fewer side effects than penicillamine. Initial worsening has not yet been reported, although it is a theoretical risk with trientine.We have introduced a new orphan drug (tetrathiomolybdate, or TM) for the initial treatment of these patients. TM has ideal properties of fast action, and doesn't cause initial worsening. Here we propose a 3 year, phase III double blind, two site, study comparing TM to trientine for initial therapy of neurologically presenting patients. We project a trial of 90 patients, 45 in each arm. The major questions to be answered are: Is there a difference in the rate of initial neurological deterioration? Is there a difference in degree of neurological recovery at years 1 and 2? Are there differences in the incidence of serious side effects? At the completion of the study, we will not only have answered the questions relating to TM vs. trientine, but we will have characterized the efficacy and toxicity of trientine, a drug already on the market, in the initial treatment setting.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE III TRIAL OF TETRATHIOMOLYBDATE (TM) IN PRIMARY BILIARY CIRRHOSIS
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN INITIAL HEPATIC WILSON'S DISEASE
PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE
PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE
海外基金